非小细胞肺癌的分子分型、驱动靶点与耐药机制
非小细胞肺癌具有显著的组织学和分子异质性。EGFR、ALK、ROS1、KRAS、BRAF、RET、MET和HER2等异常可持续激活肿瘤细胞增殖与存活信号，并形成具有不同生物学特征和药物敏感性的分子亚型。
主题
KRAS
用于检测、定量和定位抗原与抗体的技术——ELISA、免疫印迹、免疫组化与流式细胞术。以下是我们知识库中标注该主题的实验方案、常见问题与技术文章。
12 项资源 · 实验方案、常见问题与文章
Molecular Classification, Oncogenic Drivers, and Resistance Mechanisms of Non-Small Cell Lung Cancer
Non-small cell lung cancer exhibits substantial histological and molecular heterogeneity. Alterations involving EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, and other oncogenic drivers can continuously activate tumor-cell proliferation and survival signaling and generate molecular subtypes with ...
New Directions in RAS-Targeted Therapy: From Active-Conformation Inhibition to Protein Degradation
RAS mutations drive many tumors, including pancreatic cancer, colorectal cancer, and lung cancer. However, RAS was long considered difficult to drug because of its shallow structural pockets and tight GTP binding. The emergence of RAS(ON) inhibitors, molecular glues, and PROTACs has shifted RAS ...
RAS靶向治疗新方向：从活性构象抑制到蛋白降解
RAS突变驱动胰腺癌、结直肠癌和肺癌等多种肿瘤，但因结构口袋浅、GTP结合紧密，长期难以成药。RAS(ON)抑制剂、分子胶和PROTAC的出现，使RAS干预从阻断信号走向清除致癌蛋白。
2025 KRAS Targeted Drug Progress
In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
2025 KRAS靶向药物进展
在癌症研究领域，KRAS基因一直占据着重要且特殊的地位。多年来，由于其复杂的结构和功能特性，KRAS被视为 “不可成药” 靶点，然而随着科研技术的不断进步，针对KRAS的靶向治疗取得了突破性进展。
KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
KRAS抑制剂——不可成药靶点”？已是历史
KRAS（Kirsten Rat Sarcoma Viral Oncogene ...
中药分子RA-V—协同KRAS G12C抑制的潜力因子 引言：靶向KRAS G12C的瓶颈与突破口
KRAS G12C突变是结直肠癌（CRC）与非小细胞肺癌（NSCLC）等恶性肿瘤中常见的驱动突变之一。近年上市的KRAS G12C抑制剂如Adagrasib（MRTX849）和Sotorasib为患者提供了前所未有的治疗选择。
Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition
The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
GDC-1971: SHP2 Inhibitor Ushering in a New Era of Cancer Treatment
In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...
GDC-1971——SHP2抑制剂引领癌症治疗新纪元
近年来，蛋白酪氨酸磷酸酶SHP2在介导RAS驱动的MAPK信号转导过程中，已成为肿瘤学领域备受瞩目的研究靶点。其治疗方法不仅限于单药使用，还能与KRAS抑制剂共同协作，展现出良好的治疗潜力。
相关主题
常与免疫学实验一起研究的技术。
危险品化学品经营许可证（带存储）